Modern approach to basal-bolus therapy with glargine and glulisine insulin analoguesin various age groups
DCCT (Diabetes Control and Complications Trial) study established that intensified insulin therapy in multiple daily injections (MDI) or continuous insulin infusion (CSII) regimens substantially reduce both development and progression of complications in patients with type 1 diabetes mellitus (T1DM)...
Saved in:
Main Authors: | Natalya Nikitichna Volevodz, Dmitriy Nikitich Laptev, Marina Vladimirovna Shestakova |
---|---|
Format: | article |
Language: | EN RU |
Published: |
Endocrinology Research Centre
2013
|
Subjects: | |
Online Access: | https://doaj.org/article/e2aff6d78bf2450a90afabf1468d9f15 |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
Comparative efficacy assessment for various insulin regimens in patients with type 2 diabetes mellitus, ischaemic heart disease and frequent hypoglycemic events
by: Vladimir Ivanovich Kudinov, et al.
Published: (2012) -
Insulin degludec/insulin aspart is the first co-formulation of basal and prandial insulin analogues
by: Ivan Ivanovich Dedov, et al.
Published: (2014) -
Insulin glargine: pharmacokinetic and pharmacodynamic basis of clinical effect
by: Vadim Valer'evich Klimontov, et al.
Published: (2014) -
Insulin degludec: a new basal insulin analogue with an ultra-long duration of action. Safety and efficacy in Russian patients with diabetes
by: Marina Vladimirovna Shestakova, et al.
Published: (2015) -
On the safety of insulin Glargine
by: Ivan Ivanovich Dedov, et al.
Published: (2009)